59936-29-7

Basic information

• Product Name: Boc-L-Proline-methyl ester
• Synonyms: BOC-L-PROLINE METHYL ESTER;BOC-PRO-OME;Boc-L-Pro-OMe;N-BOC-poline methyl ester;N-tert-Butoxycarbonyl-L-proline methyl ester;N-alpha-t-Butyloxycarbonyl-L-proline methyl ester;Pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester;Boc-L-Proline-methyl
• CAS NO: 59936-29-7
• Molecular Formula: C₁₁H₁₉NO₄
• Molecular Weight: 229.27
• Product Categories: Pyrrole&Pyrrolidine&Pyrroline;Amino Acids;Heterocyclic Building Blocks
• Mol File: 59936-29-7.mol

Chemical Properties

• Boiling Point: 135°C/16mmHg(lit.)
• Flash Point: 128.3 °C
• Appearance: /
• Density: 1.12 g/cm³
• Vapor Pressure: 0.00232mmHg at 25°C
• Refractive Index: 1.4510 to 1.4550
• Storage Temp.: 2-8°C
• PKA: -3.35±0.40(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: Boc-L-Proline-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-L-Proline-methyl ester(59936-29-7)
• EPA Substance Registry System: Boc-L-Proline-methyl ester(59936-29-7)

Safety Data

• Hazardous Substances Data: 59936-29-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Boc-L-Proline-methyl ester is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to provide a protected and reactive building block. This allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Chemical Research:
In the field of chemical research, Boc-L-Proline-methyl ester is utilized as a versatile intermediate for the synthesis of a wide range of chemical compounds. Its unique structure allows for the exploration of new chemical reactions and the development of novel materials with potential applications in various industries.

InChI:InChI=1/C11H19NO4/c1-11(2,3)16-10(14)12-7-5-6-8(12)9(13)15-4/h8H,5-7H2,1-4H3/t8-/m0/s1

Upstream product

• 186581-53-3 diazomethane 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 67-56-1 methanol 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2133-40-6 L-proline methyl ester monohydrochloride 
• 124-41-4 sodium methylate 
• 135339-65-0 N^α,N,N-tris(tert-butoxycarbonyl)-(S)-prolinamide 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 
• 147-85-3 L-proline 
• 175446-63-6 proline acid chloride 
• 83548-46-3 (S)-1-tert-butyl 2-methyl 2,3-dihydro-1H-pyrrole-1,2-dicarboxylate 
• 616-38-6 carbonic acid dimethyl ester 

Downstream Products

• 5211-23-4 N-carbobenzyloxy-L-proline methyl ester 
• 59378-82-4 N-(tert-butoxycarbonyl)pyrrolidine-2-carboxaldehyde 
• 2577-48-2 methyl (2S)-pyrrolidine carboxylate 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 69610-41-9 Boc-L-Pro-H 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 34381-71-0 (S)-2-hydroxymethyl-1-methylpyrrolidine 
• 147-85-3 L-proline 
• 112348-45-5 1-tert-butyl 2-methyl 2-(prop-2-en-1-yl)pyrrolidine-1,2-dicarboxylate 
• 188200-05-7 1-(tertbutyloxycarbonyl)-5-(hydroxy)pyrrolidine-2-carboxylic acid methyl ester 
• 102284-41-3 (S)-tert-butyl 2-(2-chloroacetyl)pyrrolidine-1-carboxylate 
• 596846-89-8 (5S,2S)-5-allyl-pyrrolidine-2-carboxylic acid methyl ester 
• 210345-08-7 (5R,2S)-5-allyl-pyrrolidine-2-carboxylic acid methyl ester 
• 250353-59-4 (2S,R_S)-1-(tert-butoxycarbonyl)-2-(2'-p-tolylsulfinyl)acetylpyrrolidine 

Relevant articles and documents

Tetrahydropyrido [3, 4-d] pyrimidine derivative and medical application thereof

The invention relates to a compound as shown in a general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate and a preparation method thereof, and application of the compound in preparation of drugs for treating diseases related to KRas-G12C activity or expression quantity.

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY

Provided herein are methods of treating painful diabetic peripheral neuropathy, such as advanced painful DPN, in a patient by administering to the patient an effective amount of NYX-2925 or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of 3-hydroxy-2-(5-isobutyryl-1-oxo-2,5-diazaspiro[3,4]octan-2-yl)butanamide.

METHODS OF TREATING FIBROMYALGIA

Provided herein are methods of treating fibromyalgia, in a patient by administering to the patient an effective amount of NYX-2925 or a pharmaceutically acceptable salt thereof.

Direct Amidation of Esters by Ball Milling**

The direct mechanochemical amidation of esters by ball milling is described. The operationally simple procedure requires an ester, an amine, and substoichiometric KOtBu and was used to prepare a large and diverse library of 78 amide structures with modest to excellent efficiency. Heteroaromatic and heterocyclic components are specifically shown to be amenable to this mechanochemical protocol. This direct synthesis platform has been applied to the synthesis of active pharmaceutical ingredients (APIs) and agrochemicals as well as the gram-scale synthesis of an active pharmaceutical, all in the absence of a reaction solvent.

Chiral binaphthalene-aza-polycyclic ligand and preparation method thereof

The invention discloses a chiral binaphthalene aza-polycyclic ligand and a preparation method thereof. The ligand has the following structure. The preparation method comprises the following steps: (1)by taking 1, 1 '-binaphthalene 2, 2'-diphenol as a raw material, carrying out methyl protection, Tf2O protection, methylation, aromatic ring substitution and bromination reaction to obtain a 2-bromomethyl -2'-methoxy 1, 1'-binaphthalene derivative (compound V); (2) starting from aza-polycyclic carboxylic acids such as L -or D-proline, L -or D-2-piperidinecarboxylic acid, L- or D-acridine -acid and the like, carrying out derivatization to obtain various amino alcohols (compounds B); and (3) coupling the compound V and the compound B under an alkaline condition and a catalyst, and removing a protecting group to obtain the binaphthalene aza-polycyclic chiral ligand L. The ligand has central chirality and axial chirality at the same time, and can obtain higher reaction activity and enantioselectivity in asymmetric catalytic reaction. The ligands are simple to prepare, raw materials are easy to obtain, and the ligands have important significance for asymmetric synthesis.

Synthesis and photophysics of benzazole based triazoles with amino acid-derived pendant units. Multiparametric optical sensors for BSA and CT-DNA in solution

Herein we report the synthesis of a series of amino acid-derived triazoles by an organocatalytic cycloaddition reaction between azides and carbonyl compounds, catalyzed by a simple amine. These compounds present absorption maxima located in the UV-B ascribed to fully spin and symmetry allowed electronic transitions and a main fluorescence emission in the UV-A (~380 nm) with a relatively large Stokes shift (5700 cm?1). No significant solvatochromism was observed in both ground and excited states. Unexpectedly, the benzoxazole derivatives presented much higher fluorescence quantum yield values (40–80%) of compared to the sulfur analogues (3–6%). In addition, the DNA binding assays indicated that these compounds presented strong interaction with CT-DNA, which could be attributed to π-stacking and intermolecular hydrogen-bonding. The interaction of the benzazoles with bovine serum albumin (BSA) was also investigated, where a suppression mechanism was observed. In each case, docking was performed to better understand the observed interactions.

Synthesis process of chiral catalyst

The invention relates to a low-cost efficient synthesis process of both a chiral catalyst chiral (R)-(+)-2-(Diphenylhydroxymethyl)pyrrolidine and a hydrochloride thereof. According to the process, rawmaterials which can be commercially obtained easily and are environmentally friendly are used; a one-kettle method is used for operation; through esterification reaction, Boc protecting group addition on amino group, Grignard reaction and Boc protecting group removal, high-optical-purity (R)-(+)-2-(Diphenylhydroxymethyl)pyrrolidine hydrochloride is obtained. The process is simplified; the production cost is reduced; the requirements of green chemistry at present are met. The content of (R)-(+)-2-(Diphenylhydroxymethyl)pyrrolidine and the hydrochloride thereof, prepared by the process, is higher than 99.0 percent; the optical purity is not smaller than 99.5 percent; the total yield is higher than 80 percent.

Novel chiral amine oxide ligand and preparation method thereof

The invention provides a novel chiral amine oxide ligand and a preparation method thereof. The method uses a simple amino acid or an amino acid derivative as a raw material, the raw material is modified, the modified material reacts with substances such as a coupling agent and an alkali, and therefore the pincher configuration chiral ligand compound is obtained, that is, the chiral amine oxide ligand. The chiral amine oxide ligand provided by the invention has a structure of a non-simple linear chain, has a soft skeleton in the molecular structure, contains a recognition gene containing heteroatoms such as oxygen or nitrogen, and can well coordinate with a series of metals and realize high enantioselectivity and high reactivity in a non-symmetric reaction; and the preparation method is simple, the steps are few, and the raw materials are cheap and easy to obtain.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.